Clinical Trial Update: Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant [Phase 1]

View source ↗

Summary

The Phase 1 trial of a peptide-pulsed dendritic cell vaccine in combination with nivolumab and ipilimumab for diffuse hemispheric glioma, H3 G34-mutant has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Hemispheric Glioma H3 G34-mutant

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)
• peptide-pulsed dendritic cell vaccination

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Status: WITHDRAWN